The State of Intermediate Clinical Endpoints as Surrogates for Overall Survival in Prostate Cancer in 2024-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The State of Intermediate Clinical Endpoints as Surrogates for Overall Survival in Prostate Cancer in 2024

Published:2024-04 Issue: Volume: Page:
ISSN:2588-9311
Container-title:European Urology Oncology
language:en
Short-container-title:European Urology Oncology

Author:

Miszczyk Marcin^ORCID,Rajwa Paweł,Fazekas Tamás,Briganti Alberto,Karakiewicz Pierre I.,Rouprêt Morgan,Shariat Shahrokh F.

Funder

Pfizer

European Association of Urology

Publisher

Elsevier BV

Reference10 articles.

1. The validation of surrogate endpoints in meta-analyses of randomized experiments;Buyse;Biostatistics,2000

2. FDA validation of surrogate endpoints in oncology: 2005–2022;Walia;J Cancer Policy,2022

3. Metastasis-free survival is a strong surrogate of overall survival in localized prostate cancer;Xie;J Clin Oncol,2017

4. Event-free survival, a prostate-specific antigen-based composite end point, is not a surrogate for overall survival in men with localized prostate cancer treated with radiation;Xie;J Clin Oncol,2020

5. Validation of metastasis-free survival as a surrogate endpoint for overall survival in localized prostate cancer in the era of docetaxel for castration-resistant prostate cancer;Xie;Ann Oncol,2024

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role of Lutetium Radioligand Therapy in Prostate Cancer;Cancers;2024-07-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP